Market Outlook:
The global proteomics market generated revenue of approximately US$ 35.9 billion in 2024, with expectations of significant growth at a CAGR of 17.6%, reaching a valuation of US$ 181.5 billion by 2033.
Persistence Market Research projects that the reagents and kits segment will dominate, contributing a substantial market value of US$ 35.9 billion by 2024. In terms of sales, the proteomics market accounts for around 6.0% of the overall global market, which was valued at approximately US$ 514.3 billion in 2023. From 2014 to 2022, the global proteomics market experienced a notable historic CAGR of 15.5%.
The increasing prevalence of target diseases, coupled with the growing demand for personalized medicine and advanced diagnostics, are key drivers of this market's expansion. Proteomics is expected to see further growth as it becomes more widely used in drug discovery, biomarker research, and clinical diagnostics for disease detection and treatment.
For instance, in June 2022, researchers at the Indian Institute of Science (IISc) Bangalore developed a novel category of peptides, known as mini-proteins, with the potential to kill viruses such as SARS-CoV-2. According to a study published in Nature Chemical Biology, these mini-proteins can cluster virus particles, reducing their infectious capability and inhibiting their entry into human cells. As research and development activities in drug design continue to advance, the proteomics market is poised to benefit significantly.